DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing ...
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 ...
The modified amino acid levacetylleucine delivered clinically meaningful results in children and adults with the rare ...
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, ...
Families, campaigners and clinicians are calling for more public money to be provided to pay for access to drugs which could ...
On May 6, Sen. Susan Collins, a Republican from Maine, revealed that she’s had a condition called essential tremor throughout ...
Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.
MedPage Today on MSN
Is Pure Autonomic Failure a Warning Sign for Parkinson's? What a New Study Shows.
High conversion rates to Parkinson's, dementia with Lewy bodies, or multiple system atroph ...
Detailed price information for Larimar Therapeutics Inc (LRMR-Q) from The Globe and Mail including charting and trades.
Detailed price information for Neurocrine Bioscienc (NBIX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results